Nivolumab + Cisplatin + Cetuximab
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Head and Neck Squamous Cell Carcinoma (HNSCC)
Conditions
Head and Neck Squamous Cell Carcinoma (HNSCC)
Trial Timeline
Jun 1, 2016 → Feb 21, 2022
NCT ID
NCT02764593About Nivolumab + Cisplatin + Cetuximab
Nivolumab + Cisplatin + Cetuximab is a phase 1 stage product being developed by Bristol Myers Squibb for Head and Neck Squamous Cell Carcinoma (HNSCC). The current trial status is completed. This product is registered under clinical trial identifier NCT02764593. Target conditions include Head and Neck Squamous Cell Carcinoma (HNSCC).
What happened to similar drugs?
11 of 20 similar drugs in Head and Neck Squamous Cell Carcinoma (HNSCC) were approved
Approved (11) Terminated (0) Active (9)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02764593 | Phase 1 | Completed |
Competing Products
20 competing products in Head and Neck Squamous Cell Carcinoma (HNSCC)